Tirzepatide vs Semaglutide: Dosage, Efficacy & Mechanism
A side-by-side, peer-reviewed comparison of Tirzepatide and Semaglutide — mechanism, typical research dose and titration, clinical-trial efficacy, administration, and reconstitution. For research and educational purposes only.
| Attribute | Tirzepatide | Semaglutide |
|---|---|---|
| Drug class | Weight Loss | Weight Loss |
| Mechanism of action | Tirzepatide is engineered around a modified GIP backbone with C20 fatty-diacid acylation that binds albumin to produce a terminal half-life of roughly 5 days, allowing fixed-dose weekly subcutaneous injection . The molecule is a balanced agonist at the GIP… | Semaglutide is a 31-amino-acid synthetic analogue of human GLP-1 in which substitution at position 8 (alanine to α-aminoisobutyric acid) blocks DPP-4 enzymatic degradation and a C18 fatty-diacid linker at position 26 promotes reversible binding to serum… |
| Typical research dose | 2.5–15 mg once weekly (gradual 4‑week titration steps). | 0.25–2.4 mg once weekly SC (16-week titration to 2.4 mg maintenance) |
| Headline trial efficacy | SUMMIT (Packer et al., NEJM 2024) showed tirzepatide reduced the composite of cardiovascular death and worsening heart failure by 38% in patients with obesity-related HFpEF, suggesting cardiovascular benefit beyond glycemia and weight. | Real-world cohort analyses confirm 10–13% average weight loss in clinical practice at 12 months, modestly below the STEP trial average — driven by lower titration completion rates and adherence. |
| Administration | Refer to guidelines | Refer to guidelines |
| Vial sizes | 5 mg, 10 mg, 15 mg, 30 mg | 5 mg, 10 mg, 20 mg |
| Storage | Lyophilized frozen; reconstituted refrigerated for up to 28 days. | Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); use within 28 days; avoid repeated freeze–thaw cycles. |
Frequently Asked Questions
What is the difference between Tirzepatide and Semaglutide?expand_more
Tirzepatide (weight loss) and Semaglutide (weight loss) differ in receptor target and mechanism. Tirzepatide is engineered around a modified GIP backbone with C20 fatty-diacid acylation that binds albumin to produce a terminal half-life of roughly 5 days, allowing fixed-dose weekly subcutaneous injection . The molecule is a balanced agonist at the GIP… By contrast, semaglutide: Semaglutide is a 31-amino-acid synthetic analogue of human GLP-1 in which substitution at position 8 (alanine to α-aminoisobutyric acid) blocks DPP-4 enzymatic degradation and a C18 fatty-diacid linker at position 26 promotes reversible binding to serum…
How do the typical research doses of Tirzepatide and Semaglutide compare?expand_more
Tirzepatide is typically dosed at 2.5–15 mg once weekly (gradual 4‑week titration steps)., while Semaglutide is typically dosed at 0.25–2.4 mg once weekly SC (16-week titration to 2.4 mg maintenance). See each protocol for the full titration schedule.